Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy

被引:0
|
作者
Mark E. Sharkey
Ian Teo
Thomas Greenough
Natalia Sharova
Katherine Luzuriaga
John L. Sullivan
R. Pat Bucy
Leondios G. Kostrikis
Ashley Haase
Claire Veryard
Raul E. Davaro
Sarah H. Cheeseman
Jennifer S. Daly
Carol Bova
Richard T. Ellison
Brian Mady
Kwan Kew Lai
Graeme Moyle
Mark Nelson
Brian Gazzard
Sunil Shaunak
Mario Stevenson
机构
[1] University of Massachusetts Medical School,Department of Infectious Diseases
[2] Program in Molecular Medicine,Department of Pediatrics
[3] Imperial College School of Medicine,Department of Pathology
[4] Hammersmith Hospital,Department of Microbiology
[5] Du Cane Road,Division of Infectious Diseases
[6] University of Massachusetts Medical School,undefined
[7] University of Alabama at Birmingham,undefined
[8] SW W287,undefined
[9] Aaron Diamond AIDS Research Center,undefined
[10] Rockefeller University,undefined
[11] University of Minnesota,undefined
[12] University of Massachusetts/Memorial Health Care,undefined
[13] Chelsea and Westminster Hospital,undefined
来源
Nature Medicine | 2000年 / 6卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Treatment of HIV-1-infected individuals with a combination of anti-retroviral agents results in sustained suppression of HIV-1 replication, as evidenced by a reduction in plasma viral RNA to levels below the limit of detection of available assays1,2. However, even in patients whose plasma viral RNA levels have been suppressed to below detectable levels for up to 30 months, replication-competent virus can routinely be recovered from patient peripheral blood mononuclear cells3,4 and from semen5. A reservoir of latently infected cells established early in infection6 may be involved in the maintenance of viral persistence despite highly active anti-retroviral therapy3,4,5. However, whether virus replication persists in such patients is unknown. HIV-1 cDNA episomes are labile products of virus infection and indicative of recent infection events. Using episome-specific PCR, we demonstrate here ongoing virus replication in a large percentage of infected individuals on highly active anti-retroviral therapy, despite sustained undetectable levels of plasma viral RNA. The presence of a reservoir of ‘covert’ virus replication in patients on highly active anti-retroviral therapy has important implications for the clinical management of HIV-1-infected individuals and for the development of virus eradication strategies.
引用
收藏
页码:76 / 81
页数:5
相关论文
共 50 条
  • [41] Impact of highly active anti-retroviral therapy (HAART) on cytokine production and monocyte subsets in HIV-infected patients
    Amirayan-Chevillard, N
    Tissot-Dupont, H
    Capo, C
    Brunet, C
    Dignat-George, F
    Obadia, Y
    Gallais, H
    Mege, JL
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2000, 120 (01): : 107 - 112
  • [42] Influence of highly active anti-retroviral therapy (HAART) on the natural history of extra-pulmonary tuberculosis in HIV patients
    de Olalla, PG
    Martínez-González, MA
    Caylà, JA
    Jansà, JM
    Iglesias, B
    Guerrero, R
    Marco, A
    Gatell, JM
    Ocaña, I
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2002, 6 (12) : 1051 - 1057
  • [43] Progressive multifocal leukoencephalopathy treated with cidofovir in HIV-infected patients receiving highly active anti-retroviral therapy
    Portilla, J
    Boix, V
    Román, F
    Reus, S
    Merino, E
    JOURNAL OF INFECTION, 2000, 41 (02) : 182 - 184
  • [44] Tooth wear in patients treated with HIV anti-retroviral therapy
    Sehgal, Harjit Singh
    Kohli, Richie
    Pham, Edward
    Beck, Grace E.
    Anderson, Jay R.
    BMC ORAL HEALTH, 2019, 19 (1)
  • [45] Significant differences between plasma HIV-1 RNA assays in HIV-1 subtype E infected patients treated with anti-retroviral therapy
    Ruxrungtham, K
    Ubolyam, S
    Hassink, EA
    Ungsedhapand, C
    Kroon, E
    Duncombe, C
    Weverling, GJ
    Nookai, S
    Lange, J
    Cooper, D
    Phanuphak, P
    ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY, 2002, 20 (02): : 105 - 111
  • [46] Tooth wear in patients treated with HIV anti-retroviral therapy
    Harjit Singh Sehgal
    Richie Kohli
    Edward Pham
    Grace E. Beck
    Jay R. Anderson
    BMC Oral Health, 19
  • [47] DIFFERENT SERUM IGE AND EXHALED BREATH NITRIC OXIDE (NO) LEVELS AMONG PATIENTS WITH ALLERGIC ASTHMA, HIV-1 DISEASE, AND HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY (HAART).
    Nalluri, P.
    Brown, P.
    DeHovitz, J.
    Durkin, H. G.
    Nowakowski, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2009, 103 (05) : A34 - A34
  • [48] Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals
    Carpentier, A
    Patterson, BW
    Uffelman, KD
    Salit, I
    Lewis, GF
    ATHEROSCLEROSIS, 2005, 178 (01) : 165 - 172
  • [49] Immune reconstitution inflammatory syndrome after initiation of highly active anti-retroviral therapy in HIV/AIDS
    Mohanty, Kailash
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2010, 76 (03): : 301 - 304
  • [50] Safety and immunogenicity of an HIV-1 tat toxoid vaccine in HIV-1 infected volunteers on highly active anti retroviral therapy (HAART)
    Frachette, MJ
    RETROVIRUSES OF HUMAN AIDS AND RELATED ANIMAL DISEASES, 2003, : 179 - 181